collection
MENU ▼
Read by QxMD icon Read
search

Asistencias

shared collection
118 papers 0 to 25 followers
https://www.readbyqxmd.com/read/30206023/risk-of-severe-primary-graft-dysfunction-in-patients-bridged-to-heart-transplantation-with-continuous-flow-left-ventricular-assist-devices
#1
Lauren K Truby, Koji Takeda, Veli K Topkara, Hiroo Takayama, A Reshad Garan, Melana Yuzefpolskaya, Paolo Colombo, Yoshifumi Naka, Maryjane Farr
BACKGROUND: Primary graft dysfunction (PGD) remains a significant cause of post-transplant morbidity and mortality. The exact mechanism and risk factors for this phenomenon remain unknown in the contemporary era. METHODS: In this study we reviewed adult patients undergoing heart transplantation (HT) at our institution between 2009 and 2017. Severe PGD was defined as the need for mechanical circulatory support (MCS) within the first 24 hours after HT. Multivariate logistic regression analysis was used to identify risk factors for severe PGD, focusing on those bridged to transplant (BTT) with a continuous-flow left ventricular assist device (CF-LVAD)...
July 26, 2018: Journal of Heart and Lung Transplantation
https://www.readbyqxmd.com/read/30197211/aortic-regurgitation-in-patients-with-a-left-ventricular-assist-device-a-contemporary-review
#2
Nadia Bouabdallaoui, Ismail El-Hamamsy, Magali Pham, Genevieve Giraldeau, Marie-Claude Parent, Michel Carrier, Jean L Rouleau, Anique Ducharme
Aortic regurgitation (AR) developing while using a continuous-flow left ventricular assist device (CF-LVAD) affects 25% to 30% of patients within the first year of implantation and is increasingly being recognized as a cause of recurrence of symptomatic heart failure (HF). The underlying mechanisms are likely multifactorial, including changes in the leaflets of the aortic valve (AV), altered root biomechanics, and excessive left ventricular (LV) unloading, together promoting cusp remodeling and commissural fusion...
September 6, 2018: Journal of Heart and Lung Transplantation
https://www.readbyqxmd.com/read/30148976/impact-of-residual-valve-disease-on-survival-after-implantation-of-left-ventricular-assist-devices
#3
Akiko Tanaka, Hiroto Kitahara, David Onsager, Tae Song, Jayant Raikhelkar, Gene Kim, Nitasha Sarswat, Gabriel Sayer, Nir Uriel, Valluvan Jeevanandam, Takeyoshi Ota
BACKGROUND: This is a retrospective single-institutional study to investigate the impact of significant valvular regurgitation after left ventricular assist device (LVAD) implantation and the role of concomitant valve surgery during LVAD surgery. METHODS: All patients receiving LVAD (HeartMateII) during 2008 and 2015 were enrolled. The cohort was divided into two groups based on the valve-status at the end of surgery; patients without significant valvular regurgitation, no valvular regurgitation (no-VR); with significant valvular regurgitation, residual valvular regurgitation (residual-VR)...
August 24, 2018: Annals of Thoracic Surgery
https://www.readbyqxmd.com/read/30060931/risk-of-stroke-early-after-implantation-of-a-left-ventricular-assist-device
#4
Takaaki Samura, Daisuke Yoshioka, Koichi Toda, Ryoto Sakaniwa, Mikito Shimizu, Shigeru Miyagawa, Yasushi Yoshikawa, Hiroki Hata, Shunsuke Saito, Yasushi Sakata, Yoshiki Sawa
OBJECTIVE: Stroke is one of the major adverse events after left ventricular assist device implantation. Risk of stroke is the highest immediately after left ventricular assist device implantation and then increases again in chronic periods. There is no study that has analyzed risk factors for stroke in acute phase. We investigated the risk factors for stroke in the acute phase after left ventricular assist device implantation in the present study. METHODS: Between October 2005 and December 2016, 158 consecutive patients (mean age, 43 ± 14 years; 34% were women) underwent continuous-flow left ventricular assist device (50 HeartMate II [Abbott Medical, Abbott Park, Ill], 38 DuraHeart [Terumo Heart, Ann Arbor, Mich], 33 Jarvik2000 [Jarvik Heart, New York, NY], 23 EVAHEART [Sun Medical, Moriyama City, Japan], 14 HeartWare [Framingham, Mass]) implantation in our institution...
July 3, 2018: Journal of Thoracic and Cardiovascular Surgery
https://www.readbyqxmd.com/read/29304409/impeller-pump-model-derived-from-conservation-laws-applied-to-the-simulation-of-the-cardiovascular-system-coupled-to-heart-assist-pumps
#5
Yubing Shi, Theodosios Korakianitis
Previous numerical models of impeller pumps for ventricular assist devices utilize curve-fitted polynomials to simulate experimentally-obtained pressure difference versus flow rate characteristics of the pumps, with pump rotational speed as a parameter. In this paper the numerical model for the pump pressure difference versus flow rate characteristics is obtained by analytic derivation. The mass, energy and angular momentum conservation laws are applied to the working fluid passing through the impeller geometry and coupled with the turbomachine's velocity diagram...
February 1, 2018: Computers in Biology and Medicine
https://www.readbyqxmd.com/read/29936085/bloodstream-infections-in-mechanical-circulatory-support-device-recipients-in-the-international-society-of-heart-and-lung-transplantation-mechanically-assisted-circulation-support-registry-epidemiology-risk-factors-and-mortality
#6
Saima Aslam, Rongbing Xie, Jennifer Cowger, James K Kirklin, Vivian H Chu, Stephan Schueler, Theo de By, Kate Gould, Orla Morrissey, Lars H Lund, Stanley Martin, Daniel Goldstein, Margaret Hannan
BACKGROUND: We used multicenter international data from the International Society of Heart and Lung Transplantation Mechanically Assisted Circulation Support (IMACS) registry to determine bloodstream infection (BSI) event rate, independent risk factors, and association with mortality. METHODS: Included were patients registered in IMACS from January 2013 through December 2015, assessed BSI event rate of mechanical circulatory support (MCS) and non-MCS-related BSIs, and conducted univariate and multivariate analyses between BSI with baseline characteristics and mortality...
August 2018: Journal of Heart and Lung Transplantation
https://www.readbyqxmd.com/read/29905775/long-term-heart-transplant-outcomes-after-lowering-fixed-pulmonary-hypertension-using-left-ventricular-assist-devices
#7
Roxana Moayedifar, Andreas Zuckermann, Arezu Aliabadi-Zuckermann, Julia Riebandt, Philipp Angleitner, Kamen Dimitrov, Thomas Schloeglhofer, Angela Rajek, Guenther Laufer, Daniel Zimpfer
OBJECTIVES: Fixed pulmonary hypertension (fPH) is a contraindication for heart transplantation (HTX). Left ventricular assist device (LVAD) implantation as a bridge to candidacy can reverse fPH in patients with terminal heart failure by chronic left ventricular unloading. We report our institutional experience with terminal heart failure patients and fPH that were successfully bridged to candidacy and underwent subsequent HTX. METHODS: We retrospectively reviewed the data of 79 patients with terminal heart failure and fPH who were successfully bridged to candidacy for HTX with 6 different LVAD devices at our centre from October 1998 to September 2016 (Novacor n = 4, MicroMed DeBakey n = 29, DuraHeart n = 2, HeartMate II n = 14, HVAD n = 29 and MVAD n = 1)...
June 13, 2018: European Journal of Cardio-thoracic Surgery
https://www.readbyqxmd.com/read/29665860/the-use-of-cangrelor-with-heparin-for-left-ventricular-assist-device-implantation-in-a-patient-with-acute-heparin-induced-thrombocytopenia
#8
Yan K Gernhofer, Michael Ross, Swapnil Khoche, Victor Pretorius
BACKGROUND: Optimal anticoagulation strategy for cardiopulmonary bypass (CPB) in end-stage heart failure patients with heparin-induced thrombocytopenia (HIT) requiring left ventricular assist device (LVAD) implantation remains uncertain. Presently, there are no large-scale randomized studies comparing outcomes of alternative anticoagulation strategies for CPB in this patient population. A novel antiplatelet agent - cangrelor, which is a potent P2Y12 inhibitor with robust antiplatelet efficacy, rapid reversibility, and measurable drug effect, has become available since 2015...
April 17, 2018: Journal of Cardiothoracic Surgery
https://www.readbyqxmd.com/read/29666072/left-ventricular-assist-device-inflow-cannula-angle-and-thrombosis-risk
#9
Venkat Keshav Chivukula, Jennifer A Beckman, Anthony R Prisco, Todd Dardas, Shin Lin, Jason W Smith, Nahush A Mokadam, Alberto Aliseda, Claudius Mahr
BACKGROUND: As heart failure prevalence continues to increase in the setting of a static donor supply, left ventricular assist device (LVAD) therapy for end-stage heart failure continues to grow. Anecdotal evidence suggests that malalignment of the LVAD inflow cannula may increase thrombosis risk, but this effect has not been explored mechanistically or quantified statistically. Our objective is to elucidate the impact of surgical angulation of the inflow cannula on thrombogenicity. METHODS AND RESULTS: Unsteady computational fluid dynamics is used in conjunction with computational modeling and virtual surgery to model flow through the left ventricle for 5 different inflow cannula angulations...
April 2018: Circulation. Heart Failure
https://www.readbyqxmd.com/read/29734260/the-hemopump-the-first-intravascular-ventricular-assist-device
#10
Richard Wampler, O H Frazier
Development of durable left ventricular assist devices (LVADs), based on rotary flow blood pumps, began in earnest after the successful implantation of a catheter-mounted axial flow blood pump via intravascular access in 1988. This device, the Hemopump, successfully supported the circulation of a patient in cardiogenic shock secondary to acute rejection of a transplanted heart. Duration of support was 46 hours, resulting in complete recovery of cardiac function and hospital discharge. In effect, this sentinel event demonstrated that continuous-flow blood pumps could be used to support patients in cardiogenic shock...
April 19, 2018: ASAIO Journal: a Peer-reviewed Journal of the American Society for Artificial Internal Organs
https://www.readbyqxmd.com/read/29753819/use-of-the-novel-surgical-enhancement-tools-for-less-invasive-abbott-heartmate-3%C3%A2-implantation
#11
Julia Riebandt, Dominik Wiedemann, Paul Simon, Kamen Dimitrov, Guenther Laufer, Daniel Zimpfer
We present our initial experience with the novel Abbott surgical enhancement tools for less invasive HeartMate 3TM Left Ventricular Assist System (LVAS) implantation (Abbott, Chicago, IL, USA). Three new devices are introduced, a mini apical cuff with, a cuff holder and a new designed coring knife, facilitating access through left sided mini-thoracotomy.
May 10, 2018: Annals of Thoracic Surgery
https://www.readbyqxmd.com/read/29705384/trends-in-the-utilisation-and-in-hospital-mortality-associated-with-short-term-mechanical-circulatory-support-for-heart-failure-with-reduced-ejection-fraction
#12
Rajkumar Doshi, Krunalkumar Patel, Dean Decter, Rajeev Gupta, Perwaiz Meraj
Heart failure with reduced ejection fraction (HFrEF) is a systolic dysfunction with an ejection fraction below 40% and the prevalence of it is substantially increasing in the United States. Mechanical circulatory support (MCS) devices have increasingly been used for the management of HFrEF and are associated with improved outcomes. The National Inpatient Sample database was used to identify hospitalisations with mechanical circulatory support for HFrEF from 2005 to 2014. This study observed a reduction in the utilisation of intra-aortic balloon pump (IABP), which is partially replaced by percutaneous left ventricular assist device (pLVAD) and extracorporeal membrane oxygenation (ECMO) for the management of HFrEF...
April 4, 2018: Heart, Lung & Circulation
https://www.readbyqxmd.com/read/29678608/clinical-and-hemodynamic-effects-of-intra-aortic-balloon-pump-therapy-in-chronic-heart-failure-patients-with-cardiogenic-shock
#13
Justin A Fried, Abhinav Nair, Koji Takeda, Kevin Clerkin, Veli K Topkara, Amirali Masoumi, Melana Yuzefpolskaya, Hiroo Takayama, Yoshifumi Naka, Daniel Burkhoff, Ajay Kirtane, S M Dimitrios Karmpaliotis, Jeffrey Moses, Paolo C Colombo, A Reshad Garan
BACKGROUND: The role of the intra-aortic balloon pump (IABP) in acute decompensated heart failure (HF) with cardiogenic shock (CS) is largely undefined. In this study we sought to assess the hemodynamic and clinical response to IABP in chronic HF patients with CS and identify predictors of response to this device. METHODS: We retrospectively reviewed all patients undergoing IABP implantation from 2011 to 2016 at our institution to identify chronic HF patients with acute decompensation and CS (cardiac index <2...
March 20, 2018: Journal of Heart and Lung Transplantation
https://www.readbyqxmd.com/read/29655662/evaluation-of-low-intensity-anti-coagulation-with-a-fully-magnetically-levitated-centrifugal-flow-circulatory-pump-the-magentum-1-study
#14
Ivan Netuka, Peter Ivák, Zuzana Tučanová, Stanislav Gregor, Ondrej Szárszoi, Poornima Sood, Daniel Crandall, Jessica Rimsans, Jean Marie Connors, Mandeep R Mehra
BACKGROUND: The HeartMate 3 left ventricular assist system is engineered to avoid pump thrombosis, yet bleeding complications persist. We investigated the safety of low-intensity anti-coagulation in patients with the HeartMate 3. METHODS: The Minimal AnticoaGulation EvaluatioNTo aUgment heMocompatibility (MAGENTUM 1) pilot study is a prospective, single-arm study of low-intensity warfarin anti-coagulation in patients implanted with the HeartMate 3 pump. After standard warfarin anti-coagulation (international normalized ratio [INR] 2...
May 2018: Journal of Heart and Lung Transplantation
https://www.readbyqxmd.com/read/29514805/predicting-long-term-outcome-in-patients-treated-with-continuous-flow-left-ventricular-assist-device-the-penn-columbia-risk-score
#15
Edo Y Birati, Thomas C Hanff, Dawn Maldonado, E Wilson Grandin, Peter J Kennel, Jeremy A Mazurek, Esther Vorovich, Matthew Seigerman, Jessica L L Howard, Michael A Acker, Yoshifumi Naka, Joyce Wald, Lee R Goldberg, Mariell Jessup, Pavan Atluri, Kenneth B Margulies, P Christian Schulze, J Eduardo Rame
BACKGROUND: Predicting which patients are unlikely to benefit from continuous flow left ventricular assist device (LVAD) treatment is crucial for the identification of appropriate patients. Previously developed scoring systems are limited to past eras of device or restricted to specific devices. Our objective was to create a risk model for patients treated with continuous flow LVAD based on the preimplant variables. METHODS AND RESULTS: We performed a retrospective analysis of all patients implanted with a continuous flow LVAD between 2006 and 2014 at the University of Pennsylvania and included a total of 210 patients (male 78%; mean age, 56±15; mean follow-up, 465±486 days)...
March 7, 2018: Journal of the American Heart Association
https://www.readbyqxmd.com/read/29573567/comparison-of-continuous-flow-ventricular-assist-device-therapy-with-intensive-medical-therapy-in-fixed-pulmonary-hypertension-secondary-to-advanced-left-heart-failure
#16
Gayathri Kumarasinghe, Pankaj Jain, Andrew Jabbour, Jacqueline Lai, Anne M Keogh, Eugene Kotlyar, Paul Jansz, Peter S Macdonald, Christopher S Hayward
AIMS: Both ventricular assist device (VAD) and pulmonary vasodilator therapy have been shown in uncontrolled studies to improve pulmonary hypertension secondary to advanced left heart failure (Group 2 PH). This study aimed to compare haemodynamic benefits and survival in patients with fixed Group 2 PH treated with continuous-flow VAD to intensive medical therapy. METHODS AND RESULTS: Ninety-five patients listed for heart transplantation with sequential right heart catheters were studied, 24 patients having fixed Group 2 PH (as defined by cardiac index < 2...
August 2018: ESC Heart Failure
https://www.readbyqxmd.com/read/29600725/overview-of-impella-and-mechanical-devices-in-cardiogenic-shock
#17
REVIEW
Hymie Habib Chera, Menachem Nagar, Nai-Lun Chang, Carlos Morales-Mangual, George Dous, Jonathan D Marmur, Muhammad Ihsan, Paul Madaj, Yitzhak Rosen
Cardiogenic shock (CS) is a life-threatening condition associated with significant morbidity and mortality. The Impella (Abiomed Inc.) is an axial flow pump on a pigtail catheter that is placed across the aortic valve to unload the left ventricle by delivering non-pulsatile blood flow to the ascending aorta. It is used for high-risk percutaneous coronary intervention and CS. Areas covered: Percutaneous mechanical support devices are placed in a minimally invasive manner and provide life-saving assistance. We review Impella and other percutaneous devices such as intra-aortic balloon pump, TandemHeart, and extracorporeal membrane oxygenation (ECMO) and the evidence supporting their use in the setting of CS...
April 2018: Expert Review of Medical Devices
https://www.readbyqxmd.com/read/29580654/reducing-the-cost-of-left-ventricular-assist-devices-why-it-matters-and-can-it-be-done
#18
EDITORIAL
Terry Shih, Justin B Dimick
No abstract text is available yet for this article.
June 2018: Journal of Thoracic and Cardiovascular Surgery
https://www.readbyqxmd.com/read/27676411/short-term-experience-with-off-pump-versus-on-pump-implantation-of-the-heartware-left-ventricular-assist-device
#19
COMPARATIVE STUDY
Igor D Gregoric, Rajko Radovancevic, Mehmet H Akay, Mateja K Jezovnik, Sriram Nathan, Manish Patel, Jayeshkumar A Patel, Elena Nedelcu, Nghia D Nguyen, Pranav Loyalka, Biswajit Kar
Implantation of left ventricular assist devices while avoiding cardiopulmonary bypass (CPB) may decrease bleeding and improve postoperative recovery. To understand the effectiveness of this approach, we reviewed the charts of 26 patients who underwent HeartWare left ventricular assist device (HVAD) implantation without use of CPB (off-CPB group) and 22 patients who had HVAD implanted with CPB (CPB group) with an emphasis on the 30 day postoperative period. Preoperatively, both groups had similar demographic, functional, and hemodynamic characteristics...
January 2017: ASAIO Journal: a Peer-reviewed Journal of the American Society for Artificial Internal Organs
https://www.readbyqxmd.com/read/29461279/individualized-antithrombotic-therapy-in-heartware-hvad-recipients
#20
Erik N Sorensen, Hannah J Voorhees, Lynn M Dees, Si M Pham, Zachary N Kon, Bartley P Griffith, Erika D Feller
There are no evidence-based guidelines for antithrombotic therapy in left ventricular assist device patients. We evaluated the efficacy of a multi-agent, test-guided protocol, which remained consistent throughout our use of the Heartware HVAD. Thrombelastography and PFA-100 guide antiplatelet titration. Goals are normal kaolin thrombelastography maximum amplitude and prolonged PFA-100. We analyzed incidence and rates of nonprocedural bleeding, stroke, and pump thrombosis for all 81 primary Heartware left ventricular assist devices implanted since 2011...
February 15, 2018: ASAIO Journal: a Peer-reviewed Journal of the American Society for Artificial Internal Organs
label_collection
label_collection
4810
1
2
2018-03-24 23:14:53
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"